Innovate to Save Lives Act

Bill Number

H.R. 4573

Origin Chamber

House

Congress

119th Congress, Session 1

Policy Area

Taxation

Status

Introduced

Latest Action

2025-07-21: Referred to the House Committee on Ways and Means.

Last Updated

2025-08-01T16:42:52Z

AI-Generated Summary

Purpose

The "Innovate to Save Lives Act" (H.R. 4573) aims to encourage small businesses to conduct research and development (R&D) focused on addressing serious drug threats, such as fentanyl and methamphetamine, by providing them with a targeted tax credit. This legislation seeks to spur innovation in preventing, treating, and mitigating the impacts of these drugs, ultimately supporting public health efforts against the opioid and stimulant crises.

Key Provisions

• New Tax Credit: Establishes a 10% tax credit under Section 41 of the Internal Revenue Code (IRC) for "qualified drug threat mitigation research expenses" incurred by small businesses. This credit applies only to eligible research costs and is available for taxable years beginning after the date of enactment.
• Definition of Qualified Research:
• Focuses on R&D aimed at discovering information to mitigate or treat the effects of specified drugs, or to prevent, divert (e.g., intercept supply), or intervene in their use.
• Excludes clinical research (human trials) unless it follows the National Institutes of Health (NIH) guidelines for safety and ethics.
• Specified Drugs Covered:
• Fentanyl and fentanyl-related substances (chemically similar variants defined by specific structural modifications).
• Methamphetamine.
• "Emerging drugs" as designated by the Office of National Drug Control Policy (ONDCP) under existing law (21 U.S.C. 1708(c)), including any such drug if designated during the taxable year.
• Eligibility: Limited to small businesses, as defined in the IRC's existing R&D credit rules (generally companies with gross receipts under $5 million and fewer than 500 employees, though exact thresholds are referenced in the code).
• Reporting Requirement: Five years after enactment, the Government Accountability Office (GAO) must submit an anonymous report to Congress on the total credits claimed, types of research supported, and ensure the process does not hinder ongoing research.

Significant Changes to Existing Law

• Amends Section 41 of the IRC, which already provides a general R&D tax credit (up to 20% for qualified research expenses across various fields). This bill adds a new, simplified 10% credit specifically for small businesses targeting drug threats, without altering the broader credit structure.
• Introduces new definitions for "qualified drug threat mitigation research" and "specified drugs," integrating them into the IRC for the first time. This creates a targeted incentive within the existing framework, rather than a standalone program.
• No changes to the base R&D credit rates or general eligibility, but this addition prioritizes public health-related innovation for a subset of businesses.

Potential Impacts

• On Government Agencies: The Internal Revenue Service (IRS) will need to administer and verify claims for this new credit, potentially increasing administrative workload. The ONDCP's drug designations will influence eligibility, tying tax policy to federal drug control efforts. The GAO report could inform future policy adjustments.
• On Citizens: May lead to faster development of treatments, prevention tools, or interventions for drug overdoses and addiction, benefiting communities affected by the fentanyl and methamphetamine epidemics (e.g., reduced overdose deaths, improved public health outcomes).
• On Small Businesses: Provides financial relief for R&D costs, making it more feasible for startups or small firms to innovate in this area without broad revenue loss to the federal government (estimated impact not specified in the bill).
• On International Relations: Indirectly supports U.S. efforts against cross-border drug trafficking (e.g., fentanyl from abroad), but no direct foreign policy changes.

Main Stakeholders Affected

• Small Businesses: Primary beneficiaries, especially those in biotech, pharmaceuticals, or tech developing anti-drug solutions; they gain tax incentives to offset R&D expenses.
• Public Health and Research Communities: NIH-compliant researchers and organizations focused on drug mitigation; the credit could boost funding for non-clinical innovation.
• Government Entities: IRS (tax administration), ONDCP (drug designations), GAO (oversight reporting), and Congress (policy evaluation).
• General Public and Vulnerable Groups: Individuals and families impacted by drug threats, including overdose victims, addiction treatment seekers, and law enforcement dealing with diversion efforts.

Notable Legal, Constitutional, or Political Implications

• Legal: Expands the IRC's R&D credit to align tax incentives with national drug policy goals, potentially setting a precedent for targeted credits in public health crises. Ensures compliance with NIH standards to maintain research integrity and avoid unproven clinical risks.
• Constitutional: No apparent challenges; it involves standard congressional authority over taxation and spending (Article I, Section 8) to promote general welfare through innovation.
• Political: Bipartisan sponsorship (introduced by Representatives Neguse, Ciscomani, Dean, Bacon, Dexter, and Lawler) reflects cross-party consensus on the drug crisis. Could influence future appropriations or reauthorizations for drug control, emphasizing private-sector innovation over government-led programs. The GAO report promotes accountability without disclosing sensitive business data.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Rep. Neguse, Joe [D-CO-2]

Cosponsors (5)

Rep. Ciscomani, Juan [R-AZ-6], Rep. Dean, Madeleine [D-PA-4], Rep. Bacon, Don [R-NE-2], Rep. Dexter, Maxine [D-OR-3], Rep. Lawler, Michael [R-NY-17]

Recent Actions

• 2025-07-21: Referred to the House Committee on Ways and Means.
• 2025-07-21: Introduced in House
• 2025-07-21: Introduced in House

Bill Versions

• Innovate to Save Lives Act — issued 2025-07-21 — PDF (5 pages)